Delivering new horizons for heart health

Esperion is a pharmaceutical company focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with
elevated LDL-C.

Many patients with elevated LDL-C are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies: this is known as statin intolerance. Our lead product candidate, bempedoic acid (ETC-1002), is a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C — with reduced potential for muscle-related side effects associated with statin use.

Clinical Studies

Esperion launched its global Phase 3 development program, Cholesterol Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen (CLEAR), with the initiation of a long-term safety and tolerability study (1002-040) of bempedoic acid in patients with hyperlipidemia. Learn more about our planned clinical studies and results.


Meet Esperion

Our founder and chief scientific officer, Roger Newton, co-discovered the statin marketed as Lipitor® (atorvastatin) — the most commonly prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history. Learn more about our management team’s track record of success.


Statin Intolerance

It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.